MedTrace Logo

A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies

NCT03592862 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-10-01

No results posted yet for this study

Summary

To establish the safety and efficacy of HTL0018318 compared with placebo when administered once daily for 12 weeks to patients with dementia with Lewy bodies.

Conditions

  • Dementia With Lewy Bodies

Interventions

DRUG

HTL0018318

Oral capsule

DRUG

Placebo

Oral capsule

Sponsors & Collaborators

  • Sosei

    collaborator INDUSTRY

  • Nxera Pharma UK Limited

    lead INDUSTRY

Principal Investigators

  • Tim Tasker, MBBS · Heptares Therapeutics Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2020-07-31
Completion
2021-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03592862 on ClinicalTrials.gov